Format

Send to

Choose Destination
Transl Lung Cancer Res. 2018 Jun;7(3):428-436. doi: 10.21037/tlcr.2018.04.15.

A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel.

Author information

1
Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
2
Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
3
Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200240, China.
4
Sun Yat-sen University Cancer Center, Guangzhou 510030, China.
5
Center for Food and Drug Inspection of China Food and Drug Administration, The First Hospital of China Medical University, Shenyang 110001, China.
6
Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China.
7
Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
8
Department of Pulmonary Oncology, 307 Hospital of the Academy of Military Medical Sciences, Beijing 100071, China.
9
Department of Oncology, Peking University International Hospital, Beijing 102206, China.
10
Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou 310000, China.
11
Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210008, China.
12
Department of Chemotherapy, Jiangsu Cancer Hospital, Hangzhou 310000, China.
13
Department of Oncology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou 310003, China.
14
Department of Oncology, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, China.
15
Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200092, China.
16
Department of Thoracic Surgery I, Peking University Cancer Hospital and Institute, Beijing 100142, China.
17
Department of Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun 130012, China.
18
Department of Respiratory Medicine, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Chongqing 400042, China.
19
Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fujian 350001, China.
20
Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
21
Institute of Immunotherapy, Fujian Medical University, Fuzhou 350004, China.
22
Department of Oncology, Xinqiao Hospital, Third Military Medical University, Chongqing 400030, China.
23
Department of Internal Oncology, 301 General Hospital, Beijing 100853, China.
24
Department of Thoracic Surgery, The General Hospital of Guangzhou Military Command, Guangzhou 510010, China.
25
Cancer Center of Renmin Hospital, Wuhan University, Wuhan 430070, China.
26
Department of Oncology, Hu Nan Provincial Tumor Hospital, Changsha 410006, China.
27
Department of Oncology, Fujian Provincial Cancer Hospital, Fuzhou 350011, China.
28
Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang 330039, China.
29
Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China.
30
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
31
Department of Thoracic Oncology, The First Affiliated Hospital, ZheJiang University, Hangzhou 310006, China.
32
Department of Medical Oncology, Henan Cancer hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450000, China.
33
Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, China.
34
Department of Oncology, Tangdu Hospital, Fourth Military Medical University, Xi'an 710006, China.
35
Department of Thoracic Surgery, Peking University People Hospital, Beijing 100044, China.
36
Department of Oncology, Anhui Medical University, Hefei 230032, China.
37
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing 100069, China.
38
Beijing Gene+ Technology, Beijing 102208, China.

Abstract

The notable clinical success of cancer immunotherapy using checkpoint blockade suggests that it is likely to form the foundation of curative therapy for many malignancies. However, checkpoint blockades do not achieve sustained clinical response in most patients and thus amounts of problems needed to be figured out. Regarding these challenges, the 2017 Chinese Lung Cancer Summit expert panel organized a forum on the 14th Chinese Lung Cancer Summit to formally discuss these controversies. Five consensuses finally were reached to guide the application of checkpoint blockades.

KEYWORDS:

Lung cancer; consensus; immunotherapy

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Publication type

Publication type

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center